Chronic hand eczema is a persistent and often multifactorial condition that poses substantial challenges for both patients and clinicians. To help clinicians overcome these challenges, U.S. and international guidelines are evolving to better direct the diagnosis and treatment of chronic hand eczema, especially given the recent FDA approval of delgocitinib. Joining Dr. Charles Turck to review the latest guidelines and how we can use them in clinical practice is Dr. Raj Chovatiya. He's an Associate Professor at the Rosalind Franklin University Chicago Medical School as well as the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.